ChemicalBook > Product Catalog >API >Synthetic Anti-infective Drugs >Quinolones >CINOXACIN


CINOXACIN Suppliers list
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Products Intro: Product Name:1-ethyl-1,4-dihydro-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
Purity:95% (Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Mainchem Co., Ltd.
Tel: +86-0592-6210733
Products Intro: Product Name:CINOXACIN
Company Name: J & K SCIENTIFIC LTD.  
Tel: 400-666-7788 +86-10-82848833
Products Intro: Product Name:Cinoxacin
Company Name: 3B Pharmachem (Wuhan) International Co.,Ltd.  
Tel: 86-21-50328103 * 801、802、803、804 Mobile:18930552037
Products Intro: Product Name:CINOXACIN
Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
Company Name: Capot Chemical Co., Ltd  
Tel: +86 (0) 571 85 58 67 18
Products Intro: Product Name:1-ethyl-1,4-dihydro-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
Purity:98% Package:1G;5G;10G;25G Remarks:Cat No.:16235
CINOXACIN Basic information
Product Name:CINOXACIN
Synonyms:1-ETHYL-1,4-DIHYDRO-4-OXO[1,3]DIOXOLO[4,5-G]CINNOLINE-3-CARBOXYLIC ACID;CINOXACIN;TIMTEC-BB SBB003082;1-ethyl-6,7-methylenedioxy-4(1h)-oxocinnoline-3-carboxylicacid;3)dioxolo(4,5-g)cinnoline-3-carboxylicacid,1,4-dihydro-1-ethyl-4-oxo-(;cinobac;Cinoxacino;Cinoxacinum
Product Categories:Interferes with DNA SynthesisAntibiotics;Quinolones and FluoroquinolonesMore...Close...;A - KAntibiotics;Antibacterial;Antibiotics A to;Antibiotics A-FAntibiotics;CINOBAC;Antibiotics by Application;Antineoplastic and Immunosuppressive AntibioticsAntibiotics;Chemical Structure Class;Inhibits an EnzymeAntibiotics;Mechanism of Action;Spectrum of Activity
Mol File:28657-80-9.mol
CINOXACIN Chemical Properties
Melting point 261-262° (dec)
Boiling point 405.47°C (rough estimate)
density 1.3545 (rough estimate)
refractive index 1.6660 (estimate)
solubility 1 M NaOH: soluble50mg/mL
pkapKa 5.38(H2O t=25.0 I=0.025) (Uncertain)
form solid
CAS DataBase Reference28657-80-9(CAS DataBase Reference)
Safety Information
WGK Germany 2
RTECS JI4640000
ToxicityLD50 in rats (mg/kg): 4160 orally; 900 i.v. (Narama)
MSDS Information
CINOXACIN Usage And Synthesis
DefinitionChEBI: A member of the class of cinnolines that is 6,7-methylenedioxycinnolin-4(1H)-one bearing an ethyl group at position 1 and a carboxylic acid group at position 3. An analogue of oxolinic acid, it has similar antibacterial actions. It was formerly used for the treatment of urinary tract infections.
Brand nameCinobac (Lilly).
Pharmaceutical ApplicationsA cinnoline derivative formulated for oral administration. It is active against most Enterobacteriaceae, but Ps. aeruginosa, Gram-positive bacteria and anaerobes are resistant.
It is well-absorbed when given orally. Administration with food reduces the peak concentration by about one-third, but the area under the concentration–time curve (AUC) remains unchanged. Concentrations in prostatic and bladder tissues reach 60% and 80%, respectively, of the simultaneous serum concentrations.
It is almost entirely eliminated in the urine, about 40–60% as unchanged drug and the rest as metabolites, most of which have no antibacterial activity. Urinary concentrations of active drug in the first 2 h after administration of a dose is 100–500 mg/L. Elimination is reduced by probenecid and by renal impairment, the half-life rising to about 12 h in endstage renal failure.
Adverse reactions that are common to the group are reported in 4–5% of patients; these are primarily gastrointestinal tract disturbances, but rashes occur in up to 3% and CNS disturbances in less than 1%. Use is restricted to uncomplicated urinary tract infection.
Clinical Use1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5g]cinnoline-3-carboxylic acid (Cinobac) is a close congener (isostere) ofoxolinic acid (no longer marketed in the United States) andhas antibacterial properties similar to those of nalidixic andoxolinic acids.
It is recommended for the treatment of urinary tract infectionscaused by strains of Gram-negative bacteria susceptibleto these agents. Early clinical studies indicate that thedrug possesses pharmacokinetic properties superior to thoseof either of its predecessors. Thus, following oral administration,higher urinary concentrations of cinoxacin thanof nalidixic acid or oxolinic acid are achieved. Cinoxacinappears to be more completely absorbed and less proteinbound than nalidixic acid.
CINOXACIN Preparation Products And Raw materials
Tag:CINOXACIN(28657-80-9) Related Product Information
3,4-(METHYLENEDIOXY)PROPIOPHENONE 3,4-Methylenedioxyacetophenone 6-Amino-3,4-methylenedioxyacetophenone 3-BENZO[1,3]DIOXOL-5-YL-PROPAN-1-OL CHEMBRDG-BB 9071726 DIHYDROSAFROL 3-BENZO[1,3]DIOXOL-5-YL-PROPIONALDEHYDE 3-(4-HYDROXY-3-METHOXYPHENYL)PROPIONIC ACID 2'-AMINO-4'-HYDROXYACETOPHENONE 2-(2-PHENYLHYDRAZONO)ACETALDEHYDE N-Ethyl-3,4-(methylenedioxy)aniline o-tolylhydrazine 3,4-(Methylenedioxy)aniline 4-Methoxyphenylhydrazine hydrochloride 2'AMINO-4'-METHOXYACETOPHENONE 1H-CINNOLIN-4-ONE 3-(3,4-DIHYDROXYPHENYL)PROPIONIC ACID 6-aminobenzo[1,3]dioxole-5-carbaldehyde